NIOX Group PLC
82C
Company Profile
Business description
NIOX Group PLC is a medical device company that develops a range of therapies for asthma, chronic obstructive pulmonary disease, and allergy. The company has a single operating segment: NIOX. The NIOX segment relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO). Geographically, it derives a majority of its revenue from the Asia Pacific and also has a presence in the European Union, the United States, the United Kingdom, and the Rest of the world.
Contact
1 Robert Robinson Avenue
The Magdalen Centre
The Oxford Science Park
OxfordOX4 4GA
GBRT: +44 3303309356
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2025
Employees
84
Stocks News & Analysis
stocks
Overpriced ASX listed consumer electronics retailers
Solid balance sheets, lower business risk and strong sales but investors are overly optimistic.
stocks
Nvidia and AMD: Maintain fair value estimate amid reports of Meta’s negotiations to buy Google TPUs
Our update on select stocks from the Semiconductors industry.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,930.10 | 39.20 | 0.44% |
| CAC 40 | 8,099.47 | 3.04 | 0.04% |
| DAX 40 | 23,767.96 | 41.74 | 0.18% |
| Dow JONES (US) | 47,427.12 | 314.67 | 0.67% |
| FTSE 100 | 9,693.93 | 2.35 | 0.02% |
| HKSE | 25,898.24 | 47.69 | -0.18% |
| NASDAQ | 23,214.69 | 189.10 | 0.82% |
| Nikkei 225 | 50,075.89 | 91.21 | -0.18% |
| NZX 50 Index | 13,493.20 | 61.00 | 0.45% |
| S&P 500 | 6,812.61 | 46.73 | 0.69% |
| S&P/ASX 200 | 8,626.30 | 34.50 | 0.40% |
| SSE Composite Index | 3,867.27 | 7.99 | -0.21% |